Eicosapentanoic Acid Supplementation for Atherosclerotic Cardiovascular Disease Prevention.

The article explores the potential benefits of eicosapentanoic acid (EPA) supplementation in preventing atherosclerotic cardiovascular disease (ASCVD). It discusses three trials, the JELIS trial, the REDUCE-IT trial, and the RESPECT-EPA trial, which examined the effects of EPA supplementation on cardiovascular outcomes. While the JELIS and REDUCE-IT trials reported significant reductions in adverse cardiovascular events with EPA supplementation, the RESPECT-EPA trial did not show a statistically significant reduction in the primary endpoint. The article emphasizes the need for further research to determine the effectiveness of EPA supplementation in ASCVD prevention and highlights the complex effects and potential adverse effects of omega-3 fatty acid supplementation. Current guidelines recommend icosapent ethyl for high-risk patients with hypertriglyceridemia, but more research is needed to understand its mechanisms and adverse effects. [Extracted from the article]